HRP20161108T1 - Bezstanična dnk kao terapeutsko ciljno mjesto za neplodnost kod jedinki ženskog spola i dijagnostički marker - Google Patents
Bezstanična dnk kao terapeutsko ciljno mjesto za neplodnost kod jedinki ženskog spola i dijagnostički marker Download PDFInfo
- Publication number
- HRP20161108T1 HRP20161108T1 HRP20161108TT HRP20161108T HRP20161108T1 HR P20161108 T1 HRP20161108 T1 HR P20161108T1 HR P20161108T T HRP20161108T T HR P20161108TT HR P20161108 T HRP20161108 T HR P20161108T HR P20161108 T1 HRP20161108 T1 HR P20161108T1
- Authority
- HR
- Croatia
- Prior art keywords
- dnase
- female
- infertility
- treatment
- cell
- Prior art date
Links
- 208000007984 Female Infertility Diseases 0.000 title claims 7
- 206010021928 Infertility female Diseases 0.000 title claims 7
- 239000003550 marker Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 16
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 16
- 208000000509 infertility Diseases 0.000 claims 6
- 230000036512 infertility Effects 0.000 claims 6
- 231100000535 infertility Toxicity 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 5
- 210000001124 body fluid Anatomy 0.000 claims 3
- 239000010839 body fluid Substances 0.000 claims 3
- 208000021267 infertility disease Diseases 0.000 claims 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000029849 luteinization Effects 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 210000001733 follicular fluid Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000138 intercalating agent Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
Claims (17)
1. DNaza, za uporabu u liječenju neplodnosti kod jedinke ženskog spola.
2. DNaza prema patentnom zahtjevu 1, za uporabu u liječenju neplodnosti kod jedinke ženskog spola koja je povezana sa razinom bezstanične DNK koja je statistički viša od razine bezstanične DNK kod plodnih jedinki ženskog spola.
3. DNaza prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, za uporabu u liječenju neplodnosti kod jedinke ženskog spola, pri čemu navedena jedinka ženskog spola nema endometriozu.
4. DNaza prema bilo kojem od patentnih zahtjeva 1 do 3, za uporabu u liječenju neplodnosti kod jedinke ženskog spola, pri čemu je navedena DNaza rekombinantna DNaza.
5. DNaza prema bilo kojem od patentnih zahtjeva 1 do 4, za uporabu u liječenju neplodnosti kod jedinke ženskog spola, pri čemu navedena DNaza je DNaza I.
6. DNaza prema bilo kojem od patentnih zahtjeva 1 do 5, za uporabu u liječenju neplodnosti kod jedinke ženskog spola; pri čemu se navedena DNaza primenjuje intravenskim ili intramuskularnim putem.
7. DNaza prema bilo kojem od patentnih zahtjeva 1 do 6, za uporabu u liječenju neplodnosti kod jedinke ženskog spola, pri čemu se navedena DNaza primjenjuje na neplodnu jedinku ženskog spola u toku kasne lutealne faze.
8. DNaza prema bilo kojem od patentnih zahtjeva 1 do 7, za uporabu u liječenjima neplodnosti žena.
9. DNaza prema bilo kojem od patentnih zahtjeva 1 do 8, za uporabu u liječenju neplodnosti žena, pri čemu se najmanje 2500 UI DNaze 1 primjenjuje svakog dana na neplodnu ženu, u toku najmanje 4 dana.
10. DNaza prema bilo kojem od patentnih zahtjeva 1 do 9, za uporabu u liječenju neplodnosti žena, gdje se 2500 UI DNaze I primjenjuje dva puta na dan na neplodnu ženu, u toku 7 dana kasne lutealne faze.
11. Postupak za in vitro dijagnozu neplodnosti kod jedinke sisavca ženskog spola, koji sadrži slijedeće korake:
(i) određivanje razine bezstanične DNK u uzorku tjelesne tekućine iz navedene jedinke ženskog spola, i
(ii) upoređivanje navedene razine sa unaprijed određenim pragom vrijednosti,
pri čemu je razina bezstanične DNK iznad navedenog unaprijed određenog praga vrijednosti indikativna za neplodnost.
12. Postupak prema patentnom zahtjevu 11, naznačen time što navedena jedinka ženskog spola nema endometriozu.
13. Postupak prema patentnom zahtjevu 11 ili patentnom zahtjevu 12, naznačen time što, uzorak tjelesne tekućine je uzorak plazme, seruma, krvi ili folikularne tekućine.
14. Postupak prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time što je jedinka ženskog spola čovjek.
15. Postupak prema patentnom zahtjevu 14, naznačen time što, uzorak tjelesne tekućine je uzorak plazme i unaprijed određeni prag vrijednosti je sadržan između 50 ng/µl i 100 ng/µl.
16. Kit za izvođenje postupka prema bilo kojem od patentnih zahtjeva 11 do 15, koji sadrži reaktante specifične za mjerenje razine bezstanične DNK u biološkom uzorku, i reaktante specifične za mjerenje najmanje jednog drugog fiziološkog parametra u biološkom uzorku, pri čemu je navedeni fiziološki parametar izabran iz grupe koja se sastoji od razine anti-Milerovog hormona (AMH), aktivnosti telomeraze i koncentracije homocisteina.
17. Kit prema patentnom zahtjevu 16, koji sadrži najmanje DNK-interkalirajući agens i antitijelo koje specifično prepoznaje AMH.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179265 | 2012-08-03 | ||
| EP13156626 | 2013-02-25 | ||
| PCT/IB2013/056321 WO2014020564A1 (en) | 2012-08-03 | 2013-08-01 | Cell-free dna as a therapeutic target for female infertility and diagnostic marker |
| EP13762279.1A EP2879696B1 (en) | 2012-08-03 | 2013-08-01 | Cell-free dna as a therapeutic target for female infertility and diagnostic marker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161108T1 true HRP20161108T1 (hr) | 2016-11-04 |
Family
ID=49165809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161108TT HRP20161108T1 (hr) | 2012-08-03 | 2016-08-30 | Bezstanična dnk kao terapeutsko ciljno mjesto za neplodnost kod jedinki ženskog spola i dijagnostički marker |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9950040B2 (hr) |
| EP (1) | EP2879696B1 (hr) |
| JP (1) | JP6285436B2 (hr) |
| KR (1) | KR102082735B1 (hr) |
| CN (1) | CN104519906B (hr) |
| AU (1) | AU2013298144B2 (hr) |
| CA (1) | CA2880261C (hr) |
| DK (1) | DK2879696T3 (hr) |
| EA (1) | EA028855B1 (hr) |
| ES (1) | ES2588387T3 (hr) |
| HK (1) | HK1210592A1 (hr) |
| HR (1) | HRP20161108T1 (hr) |
| HU (1) | HUE030690T2 (hr) |
| IL (1) | IL236924B (hr) |
| LT (1) | LT2879696T (hr) |
| MX (1) | MX359291B (hr) |
| NZ (1) | NZ704039A (hr) |
| PL (1) | PL2879696T3 (hr) |
| PT (1) | PT2879696T (hr) |
| RS (1) | RS55087B1 (hr) |
| SI (1) | SI2879696T1 (hr) |
| WO (1) | WO2014020564A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| US8916151B2 (en) | 2005-04-25 | 2014-12-23 | Cls Therapeutics Limited | Method for treating a reduction of fertility |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| EP3161149B1 (en) * | 2014-06-27 | 2020-06-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods employing circulating dna and mirna as biomarkers for female infertility |
| ES2776360T3 (es) * | 2014-06-27 | 2020-07-30 | Inst Nat Sante Rech Med | Uso de ácidos nucleicos y miARN en un método no invasivo para determinar la calidad del embrión |
| KR101751962B1 (ko) | 2015-04-30 | 2017-06-30 | 주식회사 넥스바이오 | 세포-유리형 dna의 위암 진단 용도 |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| CN108289932A (zh) | 2015-05-22 | 2018-07-17 | D·D·格恩金 | 胞外dna作为神经变性的治疗靶点 |
| CA3067637A1 (en) | 2017-06-20 | 2018-12-27 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free dna |
| CN117138146A (zh) | 2017-09-18 | 2023-12-01 | 圣特萨斯股份公司 | 用于针对循环无细胞dna纯化血液的方法和装置 |
| CN112292453A (zh) | 2018-01-16 | 2021-01-29 | Cls治疗有限公司 | 通过肝脏表达具有脱氧核糖核酸酶（dna酶）活性的酶治疗疾病 |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| CN110144345B (zh) * | 2019-05-10 | 2022-07-15 | 上海交通大学 | 一种从卵泡液中提取cfDNA的方法 |
| EP3760740A1 (fr) | 2019-07-05 | 2021-01-06 | Hazout, André | Utilisation du niveau d'adn libre comme marqueur de l'endometriose |
| WO2021207244A1 (en) * | 2020-04-06 | 2021-10-14 | The Medical College Of Wisconsin, Inc. | Methods for assessing the severity of, and for inhibiting, pro-inflammatory responses with total cell-free dna |
| EP4026557A1 (fr) | 2021-01-06 | 2022-07-13 | Endolife | Utilisation d'une désoxyribonucléase i dans le traitement de l'endométriose chez des patientes présentant une signature épigénétique de l'endométriose sur l'adn acellulaire |
| WO2023126672A1 (en) | 2021-12-27 | 2023-07-06 | Santersus Ag | Method and device for removal of circulating cell free dna |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007131113A2 (en) * | 2006-05-03 | 2007-11-15 | Board Of Regents, The University Of Texas System | Modulation of calmodulin- binding transcription activator (camta) as a treatment for cardiac hypertrophy, heart failure, and heart injury |
| BRPI0717439A2 (pt) * | 2006-10-18 | 2013-11-19 | Periness Ltd | Composição farmacêutica, e, métodos para tratar subfertilidade masculina, para determinar um estado de fertlidade em um indivíduo do sexo masculino, para a reprodução assistida, para selecionar uma técnica de reprodução assistida e para selecionar células de esperma em uma população de células de esperma para uso em uma técnica de reprodução auxiliada. |
| EP1944611A1 (en) * | 2007-01-11 | 2008-07-16 | Université de la Méditerranée | Biomarker for the medicine and the biology of the reproduction |
| WO2013114371A1 (en) * | 2012-02-01 | 2013-08-08 | Protalix Ltd. | Dry powder formulations of dnase i |
-
2013
- 2013-08-01 RS RS20160712A patent/RS55087B1/sr unknown
- 2013-08-01 LT LTEP13762279.1T patent/LT2879696T/lt unknown
- 2013-08-01 ES ES13762279.1T patent/ES2588387T3/es active Active
- 2013-08-01 NZ NZ704039A patent/NZ704039A/en unknown
- 2013-08-01 AU AU2013298144A patent/AU2013298144B2/en active Active
- 2013-08-01 US US14/416,835 patent/US9950040B2/en active Active
- 2013-08-01 WO PCT/IB2013/056321 patent/WO2014020564A1/en active Application Filing
- 2013-08-01 DK DK13762279.1T patent/DK2879696T3/en active
- 2013-08-01 CA CA2880261A patent/CA2880261C/en active Active
- 2013-08-01 HU HUE13762279A patent/HUE030690T2/en unknown
- 2013-08-01 PT PT137622791T patent/PT2879696T/pt unknown
- 2013-08-01 CN CN201380041011.8A patent/CN104519906B/zh active Active
- 2013-08-01 PL PL13762279.1T patent/PL2879696T3/pl unknown
- 2013-08-01 KR KR1020157005041A patent/KR102082735B1/ko active IP Right Grant
- 2013-08-01 JP JP2015524896A patent/JP6285436B2/ja active Active
- 2013-08-01 SI SI201330280A patent/SI2879696T1/sl unknown
- 2013-08-01 EP EP13762279.1A patent/EP2879696B1/en active Active
- 2013-08-01 MX MX2015001538A patent/MX359291B/es active IP Right Grant
- 2013-08-01 EA EA201590115A patent/EA028855B1/ru unknown
-
2015
- 2015-01-26 IL IL236924A patent/IL236924B/en active IP Right Grant
- 2015-11-17 HK HK15111341.6A patent/HK1210592A1/zh unknown
-
2016
- 2016-08-30 HR HRP20161108TT patent/HRP20161108T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2880261A1 (en) | 2014-02-06 |
| EA201590115A1 (ru) | 2015-07-30 |
| EA028855B1 (ru) | 2018-01-31 |
| JP2015526079A (ja) | 2015-09-10 |
| HK1210592A1 (zh) | 2016-04-29 |
| CA2880261C (en) | 2021-02-02 |
| WO2014020564A1 (en) | 2014-02-06 |
| EP2879696A1 (en) | 2015-06-10 |
| SI2879696T1 (sl) | 2016-10-28 |
| PL2879696T3 (pl) | 2016-12-30 |
| ES2588387T3 (es) | 2016-11-02 |
| CN104519906A (zh) | 2015-04-15 |
| JP6285436B2 (ja) | 2018-02-28 |
| AU2013298144B2 (en) | 2018-03-08 |
| EP2879696B1 (en) | 2016-06-08 |
| US20150246103A1 (en) | 2015-09-03 |
| CN104519906B (zh) | 2016-10-05 |
| US9950040B2 (en) | 2018-04-24 |
| KR20150036776A (ko) | 2015-04-07 |
| RS55087B1 (sr) | 2016-12-30 |
| LT2879696T (lt) | 2016-09-26 |
| AU2013298144A1 (en) | 2015-02-19 |
| KR102082735B1 (ko) | 2020-02-28 |
| MX359291B (es) | 2018-09-24 |
| EA201590115A8 (ru) | 2016-04-29 |
| IL236924B (en) | 2018-05-31 |
| MX2015001538A (es) | 2015-05-11 |
| HUE030690T2 (en) | 2017-05-29 |
| NZ704039A (en) | 2018-04-27 |
| PT2879696T (pt) | 2016-09-09 |
| DK2879696T3 (en) | 2016-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161108T1 (hr) | Bezstanična dnk kao terapeutsko ciljno mjesto za neplodnost kod jedinki ženskog spola i dijagnostički marker | |
| BR112015012644A2 (pt) | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; | |
| BR112014020213A2 (pt) | biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope | |
| Aouad et al. | Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant | |
| JP2015505245A5 (hr) | ||
| JP2015530868A5 (hr) | ||
| Lee et al. | Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia | |
| BR112013030646A2 (pt) | uso diagnóstico de pró-somatostatina | |
| SG10201903424RA (en) | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | |
| BR112014016612A2 (pt) | meios e métodos para tratar ou diagnosticar cânceres positivos para a mutação idh1 r132h | |
| ES2481517A2 (es) | Método para el diagnóstico de la enfermedad de parkinson en estadios tempranos | |
| Kiayani | Association of serum testosterone and sex hormone binding globulin levels in females with acne based on its severity | |
| Loch et al. | IFNτ mediates chemotaxis, motility, metabolism and CK18 downregulation in bovine trophoblast cells in vitro via STAT1 and MAPK42/44 signaling | |
| Martínez-Montero et al. | Cholestasis and listeriosis in the third trimester of pregnancy | |
| Salmassi et al. | Evaluation of Anti-Mullerian Hormone (AMH) Cut-Off Levels in Serum and Follicular Fluid in Patients with and without Endocrinological Risk Factor in ART | |
| Pereira et al. | ABO blood type and variation in serum markers of ovarian reserve | |
| Pijnenburg et al. | FRI0398 Inflammatory myopathies with camptocormia or dropped head syndrome are associated scleromyositis with late onset and delayed diagnosis | |
| Kantasiripitak et al. | P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis | |
| RU2799789C2 (ru) | Агонисты rara для лечения омл и мдс | |
| Yumusak et al. | Does the serum E2 level change following coasting treatment strategy to prevent ovarian hyperstimulation syndrome impact cycle outcomes during controlled ovarian hyperstimulation and in vitro fertilization procedure? | |
| Lis‐Święty et al. | Morphea on the face and head: a different clinical picture and disease course in three cases. | |
| Cambiaghi et al. | Granulocyte-colony stimulation factor (G-CSF) may improve pregnancy rate in patients with repeated implantation failures | |
| Sapunarova | FACULTY OF MEDICINE | |
| Runyan | Successful Placental Development in Sheep: Contributions of CXCL12 Signaling on Vascularization and Angiogenesis | |
| Wang et al. | Proteomic analysis of arterial cord serum proteins in neonates born after in vitro fertilization (IVF) with fresh and cryopreserved/thawed embryos |